We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DNA-Antibody Hybrid Molecule Shown to Be Effective Antibacterial Agent

By LabMedica International staff writers
Posted on 18 May 2015
Image: Alphamers (purple) act as homing beacons, attracting pre-existing anti-alpha-Gal antibodies (green) to the bacterial surface (Photo courtesy of Altermune Technologies).
Image: Alphamers (purple) act as homing beacons, attracting pre-existing anti-alpha-Gal antibodies (green) to the bacterial surface (Photo courtesy of Altermune Technologies).
Image: Dr. Kary Mullis, founder of Altermune Technologies, received the Nobel Prize for chemistry in 1993 for his invention of the polymerase chain reaction (PCR) )Photo courtesy of Altermune Technologies).
Image: Dr. Kary Mullis, founder of Altermune Technologies, received the Nobel Prize for chemistry in 1993 for his invention of the polymerase chain reaction (PCR) )Photo courtesy of Altermune Technologies).
A hybrid molecule comprising an aptamer attached to a trisaccharide terminating with alpha-gal (N-acetyl-glucosamine) was shown in a proof-of-principle study to be an effective antibacterial agent.

Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies, as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications. Relative to monoclonal antibodies, aptamers are small, stable, and non-immunogenic.

Humans do not express the galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-Gal) epitope. However, as a result of exposure to alpha-Gal in the environment, humans develop a large quantity of circulating antibodies that are specific for this trisaccharide.

Investigators at the University of California, San Diego (USA) developed a DNA aptamer that was able to bind to group A Streptococcus (GAS) bacteria by recognition of a conserved region of the surface-anchored M protein. To the 5′ end of this aptamer they conjugated an alpha-Gal epitope. This hybrid molecule was termed an "alphamer." The intent was that the aptamer segment of the alphamer would attach the molecule to the target bacterium while the alpha-Gal fragment would bind to the body's normally circulating anti-alpha-Gal antibodies.

In a paper published in the May 5, 2015, online edition of the Journal of Molecular Medicine the investigators showed that an anti-GAS alphamer could recruit anti-Gal antibodies to the streptococcal surface in an alpha-Gal-specific manner, elicit uptake and killing of the bacteria by human phagocytes, and slow growth of invasive GAS organisms in human whole blood.

These results constituted the first in vitro proof of concept that alphamers had the potential to redirect preexisting antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response.

"We are picturing a future in which doctors have a case full of pathogen-specific alphamers at their disposal," said senior author Dr. Victor Nizet, professor of pediatrics and pharmacy at the University of California, San Diego. "They see an infected patient, identify the causative bacteria, and pull out the appropriate alphamer to instantly enlist the support of the immune system in curing the infection."

The alphamer concept was attributed to contributing author Dr. Kary Mullis, winner of the 1993 Nobel Prize for chemistry for his invention of the polymerase chain reaction (PCR), technique. Dr. Mullis has established a biotech company, Altermune Technologies (Irvine, CA, USA), to develop alphamers into commercially viable therapeutic tools.

Related Links:

University of California, San Diego
Altermune Technologies


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more